SELP and ischemic stroke: Of the two P-selectin targeted complement inhibitors we characterized, one had an additional anti-coagulative property, which while detrimental for treating hemorrhagic conditions, such as GMH, has therapeutic potential for treating neuroinflammatory pathologies that include a thrombotic event, such as ischemic stroke or indeed other non-CNS thrombotic pathologies in which complement plays a role.